Welcome to our dedicated page for KORU Medical Systems SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems (KRMD) reported Q3 2025 results and updated its full‑year 2025 financial guidance via a press release furnished as Exhibit 99.1. The quarter covered the period ended September 30, 2025, and a conference call was scheduled for November 12, 2025 at 4:30 p.m. Eastern Time.
The company highlighted use of non‑GAAP measures, including adjusted EBITDA and adjusted diluted EPS, with definitions provided and reconciliations to GAAP included in the press release. Management views these metrics as helpful for comparing ongoing operations. The information under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities.
KORU Medical Systems (KRMD) reported an insider equity transaction. On 10/16/2025, the President and CEO was issued 29,463 shares of common stock at $4.08 per share under her employment agreement as the stock portion of the 2024 annual bonus (30% stock, 70% cash).
Following the transaction, she beneficially owned 1,052,626 shares. This includes 200,000 restricted stock awards that vest based on a market capitalization schedule prior to 3/15/27, and 600,000 restricted stock awards that vest based on net sales growth targets for fiscal years ended 12/31/22 through 12/31/25.
Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share. Following the transaction the reporting person beneficially owned 41,688 shares. The filing is a Form 4 statement of changes in beneficial ownership and was signed by Thomas Adams as attorney-in-fact.
KORU Medical Systems director Matin Shahriar reported a purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. Following this transaction the reporting person beneficially owns 91,520 shares. The filing was submitted on Form 4 and signed by an attorney-in-fact.
Fletcher R. John, identified as Chairman of the Board of KORU Medical Systems, Inc. (KRMD), reported a purchase of 5,874 shares of the issuer's common stock at a price of $3.83 per share on 10/02/2025. After the transaction he beneficially owns 217,720 shares. The Form 4 notes the filing is submitted under a previously granted power of attorney and clarifies it should not be taken as an admission of beneficial ownership under Section 16. No derivative transactions or other security classes are reported.
KORU Medical Systems director Robert Cascella reported an open-market purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. After the transaction he beneficially owned 88,531 shares. The Form 4 was signed by an attorney-in-fact and includes a standard remark that a power of attorney has been previously filed.
Joseph M. Manko Jr., a director and reported 10% owner, filed a Form 4 for KORU Medical Systems, Inc. (KRMD). The filing shows a transaction dated 09/30/2025 where he acquired 3,916 shares of Common Stock at a reported price of $0, and reports 5,871,335 shares beneficially owned indirectly through Horton Capital Partners Fund, LP. The Form also reports a disposition of 517,200 shares.
The Form 4 is signed by Mr. Manko with signature dates of 10/02/2025. The filing references an Exhibit 99.1 for explanations of two notes tied to the reported acquisition and indirect ownership. No additional financial metrics, option holdings, or exercise/expiry dates are disclosed in the filing text provided.
KORU Medical Systems, Inc. filed a Form S-8 to register common stock related to equity awards granted to its incoming Chief Commercial Officer. The company granted an Individual Restricted Stock Agreement for 300,000 shares and a Non‑Qualified Stock Option Award covering 600,000 shares, granted July 28, 2025 and August 1, 2025 respectively, each subject to vesting and potential acceleration, to Adam Kalbermatten as an inducement to join as CCO. The registration statement specifically registers the common stock issuable upon exercise of those options and incorporates by reference the company’s annual report and other Exchange Act filings and the description of its common stock. The filing also discloses charter provisions limiting director liability and indemnification provisions, and notes that indemnification for Securities Act liabilities may be unenforceable under SEC precedent.
Linda M. Tharby, who serves as President, CEO and a director of KORU Medical Systems (KRMD), was awarded equity under the company’s 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program. The awards reported include 55,911 restricted stock units that vest one-fourth on May 12, 2026 and annually thereafter, 111,729 performance-based restricted stock units payable at target (the payout may range from 0%-150% of the reported amount and is further multiplied by 0.5x–1.5x depending on performance) that vest based on achievement as of December 31, 2027, and an option to buy 94,772 shares at a $3.21 exercise price expiring May 12, 2035 with one-fourth vesting annually beginning May 12, 2026.
The transaction date for these awards is reported as 05/12/2025. The filing notes that vesting may accelerate upon a change in control and clarifies the reported RSU amounts represent contingent rights or target awards rather than immediately issued shares.
KORU Medical Systems insider award summary: Christopher Pazdan, the company’s Chief Operating Officer, received equity awards under the 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program on 05/12/2025. The awards include two restricted stock unit grants of 21,308 RSUs each (total 42,616 RSUs); one grant vests time-based one-fourth on 05/12/2026 and annually thereafter, the other vests based on performance measured as of 12/31/2027 with potential payout from 0% to 150% of target and specified multipliers, and both convert to one share per vested unit. Pazdan also received an option for 36,077 shares with a $3.21 exercise price that vests one-fourth on 05/12/2026 and annually thereafter and expires on 05/12/2035. The filing states these awards were granted pursuant to the Company’s equity plan.